Abstract
The search for antiepileptic compounds with more selective activity and lower toxicity continues to be an area of intensive investigation in medicinal chemistry. This review describes new anticonvulsant agents representing various structures for which the precise mechanism of action is still not known. Many of the compounds presented in this review have been tested according to the procedure established by the Antiepileptic Drug Development Program of the Epilepsy Branch of the National Institute of Neurological Disorders and Stroke, National Institute of Health, USA. The newer agents include sulfonamides, amino acids, amides (analogs of γ-vinyl GABA, N-benzylamides, 2,6-dimethylanilides, carboxyamides, hydroxyamides, alkanoamides); heterocyclic agents ((arylalkyl)imidazoles, pyrrolidin-2,5-diones, lactams, semi- thiosemicarbazones, thiadiazoles, quinazolin-4(3H)-ones, 2,5-disubstituted 1,2,4-thadiazoles, xanthones, derivatives of isatin) and enaminones. These new structural classes of compounds can prove useful for the design of future targets and development of new drugs.
Keywords: anticonvulsant agents, structure - activity - relationships
Current Topics in Medicinal Chemistry
Title: New Anticonvulsant Agents
Volume: 5 Issue: 1
Author(s): Barbara Malawska
Affiliation:
Keywords: anticonvulsant agents, structure - activity - relationships
Abstract: The search for antiepileptic compounds with more selective activity and lower toxicity continues to be an area of intensive investigation in medicinal chemistry. This review describes new anticonvulsant agents representing various structures for which the precise mechanism of action is still not known. Many of the compounds presented in this review have been tested according to the procedure established by the Antiepileptic Drug Development Program of the Epilepsy Branch of the National Institute of Neurological Disorders and Stroke, National Institute of Health, USA. The newer agents include sulfonamides, amino acids, amides (analogs of γ-vinyl GABA, N-benzylamides, 2,6-dimethylanilides, carboxyamides, hydroxyamides, alkanoamides); heterocyclic agents ((arylalkyl)imidazoles, pyrrolidin-2,5-diones, lactams, semi- thiosemicarbazones, thiadiazoles, quinazolin-4(3H)-ones, 2,5-disubstituted 1,2,4-thadiazoles, xanthones, derivatives of isatin) and enaminones. These new structural classes of compounds can prove useful for the design of future targets and development of new drugs.
Export Options
About this article
Cite this article as:
Malawska Barbara, New Anticonvulsant Agents, Current Topics in Medicinal Chemistry 2005; 5 (1) . https://dx.doi.org/10.2174/1568026053386944
DOI https://dx.doi.org/10.2174/1568026053386944 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Current Pharmaceutical Design CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Cofactors and Metabolites as Protein Folding Helpers in Metabolic Diseases
Current Topics in Medicinal Chemistry Derivatives of Deoxypodophyllotoxin Induce Apoptosis through Bcl-2/Bax Proteins Expression
Anti-Cancer Agents in Medicinal Chemistry Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Alzheimer’s Disease and Autistic Spectrum Disorder: Is there any Association?
CNS & Neurological Disorders - Drug Targets AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Array-Comparative Genomic Hybridization Analysis of a Cohort of Saudi Patients with Epilepsy
CNS & Neurological Disorders - Drug Targets (Section B: Integrated Function of Drug Transporters In Vivo) Drug Transport at the Blood-Brain Barrier and the Choroid Plexus
Current Drug Metabolism Meet Our Regional Editor:
Current Drug Discovery Technologies Cognitive Identity in Schizophrenia: Vision, Space, and Body Perception from Prodrome to Syndrome
Current Psychiatry Reviews Synthesis of the Neurotransmitter 4-Aminobutanoic Acid (GABA) from Diethyl Cyanomalonate
Letters in Drug Design & Discovery Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design Sodium Channel Blocking Activity and In-vivo Testing of New Phenylimidazole Derivatives
Letters in Drug Design & Discovery Fad Diets: Dietary Dilemmas, Predicaments, and Recommendations for its Use
Current Nutrition & Food Science Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry